FDA Approves Tecentriq Hybreza Anti-PD-(L)1 Cancer Immunotherapy
September 12, 2024FDA Approves Ocrevus Zunovo. A Twice-A-Year Subcutaneous Injection for PeopleWith Relapsing and Progressive Multiple Sclerosis
September 13, 2024September 13, 2024 – Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
Eczema inflammation under the skin can lead to symptoms seen and felt on the outside. Ebglyss works by targeting eczema inflammation throughout the body that can lead to dry, itchy, and irritated skin.
Source: Eli Lilly and Company